Fig. 3. Expression ratio of urinary miR-1913 to miR-3659 in the validation cohort. (A) All patients. (B) Patients within the PSA gray zone (3–10 ng/mL). BPH, benign prostate hyperplasia; PCa, prostate cancer; PSA, prostate-specific antigen. A p-value was determined by the Mann–Whitney U-test. ^**p<0.01.